Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target
Open Access
- 1 January 2018
- journal article
- review article
- Published by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 21 (1), 1-11
- https://doi.org/10.5223/pghn.2018.21.1.1
Abstract
The emergence of mucosal healing as a treatment goal that could modify the natural course of Crohn's disease and the accumulating evidence showing that biologics are most effective in achieving mucosal healing, along with the success of early treatment regimens for rheumatoid arthritis, have led to the identification of early Crohn's disease and development of the concept of catching the therapeutic window during the early disease course. Thus, an increasing number of pediatric gastroenterologists are adopting an early biologic treatment strategy with or without an immunomodulator. Although early biologic treatment is effective, cost and overtreatment are issues that limit its early use. Currently, there are insufficient data on who will benefit most from early biologics, as well as on who will not need early or even any biologics. For now, top-down biologics should be considered for patients with currently known high-risk factors of poor outcomes. For other patients, close, objective monitoring and accelerating the step-up process by means of a treat-to-target approach seems the best way to catch the therapeutic window in early pediatric Crohn's disease. The individual benefits of immunomodulator addition during early biologic treatment should be weighed against its risks and decision on early combination treatment should be made after comprehensive discussion with each patient and guardian.Keywords
This publication has 70 references indexed in Scilit:
- Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn’s Disease Under Combined Immunosuppression: Escalation versus Early TreatmentJournal of Crohn's and Colitis, 2016
- Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trialThe Lancet, 2015
- Risk of Lymphoma, Colorectal and Skin Cancer in Patients with IBD Treated with Immunomodulators and BiologicsInflammatory Bowel Diseases, 2015
- Predicting Endoscopic Crohnʼs Disease Activity Before and After Induction Therapy in ChildrenInflammatory Bowel Diseases, 2015
- Risks of Serious Infection or Lymphoma With Anti–Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic ReviewClinical Gastroenterology and Hepatology, 2014
- Mucosal healing in inflammatory bowel diseases: a systematic reviewGut, 2012
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialThe Lancet, 2008
- Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurineGut, 2005
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Distinct cytokine patterns in early and chronic ileal lesions of Crohn's diseaseGastroenterology, 1997